Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel liposomes + tegafur versus oxaliplatin + tegafur as neoadjuvant chemotherapy for locally advanced gastric cancer
ChiCTR-IPR-17012201Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Aug 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in gastric cancer (GC) and gastric adenocarcinoma comparing Paclitaxel liposomes plus tegafur group with Oxaliplatin plus tegafur group (2 arms). Primary endpoint: Disease control rate. Started Aug 2017; status: recruiting.
02
Drugs
liposomal paclitaxeltegafuroxaliplatin
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-IPR-17012201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012201.